B. Metzler Seel. Sohn & Co. Holding Ag Cytokinetics Inc Transaction History
B. Metzler Seel. Sohn & Co. Holding Ag
- $10.1 Trillion
- Q3 2024
A detailed history of B. Metzler Seel. Sohn & Co. Holding Ag transactions in Cytokinetics Inc stock. As of the latest transaction made, B. Metzler Seel. Sohn & Co. Holding Ag holds 4,698 shares of CYTK stock, worth $146,624. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,698Holding current value
$146,624% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CYTK
# of Institutions
408Shares Held
127MCall Options Held
3.66MPut Options Held
900K-
Black Rock Inc. New York, NY14.7MShares$458 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$370 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD9.96MShares$311 Million0.26% of portfolio
-
Wellington Management Group LLP Boston, MA7.99MShares$249 Million0.06% of portfolio
-
State Street Corp Boston, MA6.09MShares$190 Million0.01% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $2.94B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...